These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 23421567)

  • 1. Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment.
    Douglas Bruce R; Moody DE; Chodkowski D; Andrews L; Fang WB; Morrison J; Parsons TL; Friedland GH
    Am J Drug Alcohol Abuse; 2013 Mar; 39(2):80-5. PubMed ID: 23421567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment.
    Bruce RD; Winkle P; Custodio JM; Wei LX; Rhee MS; Kearney BP; Ramanathan S; Friedland GH
    J Acquir Immune Defic Syndr; 2013 Aug; 63(4):480-4. PubMed ID: 23599011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone.
    Bruce RD; Altice FL; Moody DE; Lin SN; Fang WB; Sabo JP; Wruck JM; Piliero PJ; Conner C; Andrews L; Friedland GH
    Drug Alcohol Depend; 2009 Dec; 105(3):234-9. PubMed ID: 19726139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone.
    Sekar V; Tomaka F; Lefebvre E; De Pauw M; Vangeneugden T; van den Brink W; Hoetelmans R
    J Clin Pharmacol; 2011 Feb; 51(2):271-8. PubMed ID: 20421512
    [No Abstract]   [Full Text] [Related]  

  • 5. Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone.
    Bruce RD; Moody DE; Fang WB; Chodkowski D; Andrews L; Friedland GH
    Am J Drug Alcohol Abuse; 2011 Jul; 37(4):224-8. PubMed ID: 21438849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir.
    Bruce RD; Altice FL; Moody DE; Morse GD; Andrews L; Lin SN; Fang WB; Ma Q; Friedland GH
    J Acquir Immune Defic Syndr; 2010 Aug; 54(5):511-4. PubMed ID: 20672450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence.
    Orman JS; Keating GM
    Drugs; 2009; 69(5):577-607. PubMed ID: 19368419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals.
    Amass L; Pukeleviciene V; Subata E; Almeida AR; Pieri MC; D'Egidio P; Stankova Z; Costa A; Smyth BP; Sakoman S; Wei Y; Strang J
    Addiction; 2012 Jan; 107(1):142-51. PubMed ID: 21749526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.
    Mammen K; Bell J
    Expert Opin Pharmacother; 2009 Oct; 10(15):2537-44. PubMed ID: 19708849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioavailability of buprenorphine from crushed and whole buprenorphine (subutex) tablets.
    Simojoki K; Lillsunde P; Lintzeris N; Alho H
    Eur Addict Res; 2010; 16(2):85-90. PubMed ID: 20130408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine and naloxone interactions in methadone maintenance patients.
    Mendelson J; Jones RT; Welm S; Brown J; Batki SL
    Biol Psychiatry; 1997 Jun; 41(11):1095-101. PubMed ID: 9146820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preference for buprenorphine/naloxone and buprenorphine among patients receiving buprenorphine maintenance therapy in France: a prospective, multicenter study.
    Daulouède JP; Caer Y; Galland P; Villeger P; Brunelle E; Bachellier J; Piquet JM; Harbonnier J; Leglise Y; Courty P
    J Subst Abuse Treat; 2010 Jan; 38(1):83-9. PubMed ID: 19800758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine may not be as safe as you think: a pediatric fatality from unintentional exposure.
    Kim HK; Smiddy M; Hoffman RS; Nelson LS
    Pediatrics; 2012 Dec; 130(6):e1700-3. PubMed ID: 23129079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients.
    McCance-Katz EF; Moody DE; Prathikanti S; Friedland G; Rainey PM
    Drug Alcohol Depend; 2011 Nov; 118(2-3):326-34. PubMed ID: 21596492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers.
    Middleton LS; Nuzzo PA; Lofwall MR; Moody DE; Walsh SL
    Addiction; 2011 Aug; 106(8):1460-73. PubMed ID: 21395892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of the combination tablet of buprenorphine and naloxone.
    Chiang CN; Hawks RL
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S39-47. PubMed ID: 12738349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
    Anderson MS; Kakuda TN; Hanley W; Miller J; Kost JT; Stoltz R; Wenning LA; Stone JA; Hoetelmans RM; Wagner JA; Iwamoto M
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4228-32. PubMed ID: 18838586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of telaprevir on the pharmacokinetics of buprenorphine in volunteers on stable buprenorphine/naloxone maintenance therapy.
    Luo X; Trevejo J; van Heeswijk RP; Smith F; Garg V
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3641-7. PubMed ID: 22564847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials.
    Ciraulo DA; Hitzemann RJ; Somoza E; Knapp CM; Rotrosen J; Sarid-Segal O; Ciraulo AM; Greenblatt DJ; Chiang CN
    J Clin Pharmacol; 2006 Feb; 46(2):179-92. PubMed ID: 16432270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir.
    McCance-Katz EF; Moody DE; Smith PF; Morse GD; Friedland G; Pade P; Baker J; Alvanzo A; Jatlow P; Rainey PM
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S235-46. PubMed ID: 17109310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.